deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02581215

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198

Sponsor: Eli Lilly and Company

Conditions Pancreatic Cancer
Interventions Placebo Ramucirumab mFOLFIRINOX
Updated 18 times since 2017 Last updated: Dec 19, 2024 Started: Sep 11, 2016 Primary completion: Aug 5, 2021 Completion: Jan 27, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pancreatic Cancer and is currently completed. Eli Lilly and Company leads this study, which shows 18 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Nov 2019 · 5 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Feb 2022 · 12 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Jan 2023 · 10 months · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – present · 17 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2025 — Present [monthly]

    Completed PHASE2

    Status: Unknown → Completed

  2. Jan 2025 — Feb 2025 [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  3. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 13 earlier versions

  1. Mar 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jun 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  9. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  10. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  11. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  12. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
  • Hoosier Cancer Research Network
  • Walid Shaib, MD
Data source: Hoosier Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations